JETEMA, Co., Ltd.

KOSDAQ:A216080 Stock Report

Market Cap: ₩320.5b

JETEMA Past Earnings Performance

Past criteria checks 2/6

There is insufficient data on JETEMA's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate15.2%
Return on equity26.6%
Net Margin31.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 23
JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News

Recent updates

JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 23
JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News

Is JETEMA, Co., Ltd.'s (KOSDAQ:216080) Shareholder Ownership Skewed Towards Insiders?

Feb 25
Is JETEMA, Co., Ltd.'s (KOSDAQ:216080) Shareholder Ownership Skewed Towards Insiders?

JETEMA (KOSDAQ:216080) Is Carrying A Fair Bit Of Debt

Jan 21
JETEMA (KOSDAQ:216080) Is Carrying A Fair Bit Of Debt

The JETEMA (KOSDAQ:216080) Share Price Has Gained 110%, So Why Not Pay It Some Attention?

Dec 17
The JETEMA (KOSDAQ:216080) Share Price Has Gained 110%, So Why Not Pay It Some Attention?

Revenue & Expenses Breakdown

How JETEMA makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A216080 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2463,87720,23315,77911,544
31 Mar 2462,55114,19614,81111,026
31 Dec 2358,71613,96613,24910,223
30 Sep 2357,603-21,99013,9228,782
30 Jun 2355,439-18,14413,7077,449
31 Dec 2245,9941,45511,9556,263

Quality Earnings: A216080 has high quality earnings.

Growing Profit Margin: A216080 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if A216080's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare A216080's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.

Earnings vs Industry: A216080 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.6%).


Return on Equity

High ROE: Whilst A216080's Return on Equity (26.63%) is high, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Discover strong past performing companies